- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02902562
Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound (CEUS)
Quantitative Assessment of Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Inflammatory arthritis affects approximately 1% of the world population and can lead to significant pain and disability. Although radiographs can identify characteristic patterns of joint space narrowing and erosive changes, these findings are typically late findings and represent irreversible damage. With the development of disease modifying anti-rheumatic drugs (DMARDs), the goal is now to identify the pre-erosive inflammatory features and identify the patients that progress further into severe functional debility if not treated immediately.
MRI with gadolinium enhancement is proven to be very effective in early detection of soft tissue, bone erosions, synovitis, the integrity of ligaments, cartilage and bone marrow edema. However, MRI is expensive, may be impractical for assessing multiple joints and has relatively long examination time. Some patients may have claustrophobia and some may have contraindications to gadolinium administration. The investigators overarching goal is to determine whether the perfusion information provided by novel ultrasound based techniques such as, contrast enhanced ultrasound and superb microvascular imaging, can be used for assessment of treatment response to DMARD therapy for inflammatory arthritis. The recent advances in evaluation of vascularity of the tumors using contrast ultrasound technique can also be applied to rheumatological diseases. It is ideal to develop a sensitive imaging technique that can be routinely available and is relatively cheap. Ultrasound is available and has low cost and can be used for assessment of treatment response to DMARD therapy
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- USC Department of Radiology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients (≥ 18 years of age) that meet diagnostic criteria for an inflammatory arthritis.
- Clinical suspicion of active synovitis involving at least one target joint.
- Patients competent to sign study specific Informed Consent.
- Patients willing to comply with protocol requirements.
- Intent to treat with disease-modifying anti-rheumatic drugs (DMARDs).
Exclusion Criteria:
- Patients who are pregnant or less than 18 years of age.
- Patients who have a known cardiac shunt or pulmonary hypertension.
- Patients with any known hypersensitivity to perflutren or gadolinium contrast agents or renal insufficiency (GFR < 30 mL/min).
- Patients who cannot consent for themselves.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Study Visit
You will have a Contrast Enhanced Ultrasound (CEUS) and contrast Magnetic Resonance Imaging (MRI) which will take about 2 hours.
|
An intravenous line (IV) line will be inserted into a vein in your arm.
You will be asked to lie on a table for the ultrasound imaging.
First, a regular ultrasound (without contrast) will be performed and the images will be recorded.
For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line.
We will perform another ultrasound and the images will be recorded
For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time.
There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces.
A technician will be present at all times during the examination to communicate with you about how you are feeling.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Kappa coefficient
Time Frame: 12 months
|
To assess the inter-reader agreement as well as the agreement between CEUS versus MRI determined treatment response.
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: George R Matcuk, MD, University of Southern California
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS-15-00377
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on Contrast Enhanced Ultrasound (CEUS)
-
St. Joseph's Healthcare HamiltonMcMaster UniversityRecruiting
-
Mayo ClinicCompleted
-
Peking Union Medical College HospitalRecruitingUltrasonography | Pheochromocytoma, Metastatic | Paraganglioma, Malignant | Pheochromocytoma MalignantChina
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)RecruitingCervical Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Oregon...WithdrawnNephrolithiasis | Ultrasonography
-
Mayo ClinicCompletedTransplantation, KidneyUnited States
-
Children's Hospital of PhiladelphiaBracco Diagnostics, IncRecruitingDevelopmental Dysplasia of the HipUnited States
-
Kibo NamNational Cancer Institute (NCI)RecruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States
-
Liverpool University Hospitals NHS Foundation TrustCompletedAbdominal Aortic Aneurysm | EndoleakUnited Kingdom
-
Peking Union Medical College HospitalRecruitingPancreatic Cancer | Ultrasonography | First-line ChemotherapyChina